These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 35609768)

  • 1. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
    Gulliver C; Hoffmann R; Baillie GS
    Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
    Neeb A; Herranz N; Arce-Gallego S; Miranda S; Buroni L; Yuan W; Athie A; Casals T; Carmichael J; Rodrigues DN; Gurel B; Rescigno P; Rekowski J; Welti J; Riisnaes R; Gil V; Ning J; Wagner V; Casanova-Salas I; Cordoba S; Castro N; Fenor de la Maza MD; Seed G; Chandran K; Ferreira A; Figueiredo I; Bertan C; Bianchini D; Aversa C; Paschalis A; Gonzalez M; Morales-Barrera R; Suarez C; Carles J; Swain A; Sharp A; Gil J; Serra V; Lord C; Carreira S; Mateo J; de Bono JS
    Eur Urol; 2021 Feb; 79(2):200-211. PubMed ID: 33176972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
    Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
    Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
    Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
    Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting DNA Damage Response in Prostate and Breast Cancer.
    Wengner AM; Scholz A; Haendler B
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158305
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Rafiei S; Fitzpatrick K; Liu D; Cai MY; Elmarakeby HA; Park J; Ricker C; Kochupurakkal BS; Choudhury AD; Hahn WC; Balk SP; Hwang JH; Van Allen EM; Mouw KW
    Cancer Res; 2020 Jun; 80(11):2094-2100. PubMed ID: 32127357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of hypersensitivity to oxidative DNA damage in ATM defective cells induced by potassium bromate by inhibition of the Poly (ADP-ribose) polymerase (PARP).
    Mosesso P; Piane M; Pepe G; Cinelli S; Chessa L
    Mutat Res Genet Toxicol Environ Mutagen; 2018 Dec; 836(Pt A):117-123. PubMed ID: 30389154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic action of combined PARP and ATR inhibition in prostate cancer with ATM loss.
    Tregunna R
    Nat Rev Urol; 2021 Jan; 18(1):4. PubMed ID: 33262506
    [No Abstract]   [Full Text] [Related]  

  • 9. ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.
    Zhou Y; Börcsök J; Adib E; Kamran SC; Neil AJ; Stawiski K; Freeman D; Stormoen DR; Sztupinszki Z; Samant A; Nassar A; Bekele RT; Hanlon T; Valentine H; Epstein I; Sharma B; Felt K; Abbosh P; Wu CL; Efstathiou JA; Miyamoto DT; Anderson W; Szallasi Z; Mouw KW
    Sci Adv; 2023 Nov; 9(47):eadg2263. PubMed ID: 37992168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
    Cui Y; Palii SS; Innes CL; Paules RS
    Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer.
    Shao J; Huang L; Lai W; Zou Y; Zhu Q
    Molecules; 2023 Jun; 28(11):. PubMed ID: 37298997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.
    Turchick A; Zimmermann A; Chiu LY; Dahmen H; Elenbaas B; Zenke FT; Blaukat A; Vassilev LT
    Mol Cancer Ther; 2023 Jul; 22(7):859-872. PubMed ID: 37079339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-Ribose) Polymerase-1 inhibition potentiates cell death and phosphorylation of DNA damage response proteins in oxidative stressed retinal cells.
    Martín-Guerrero SM; Casado P; Muñoz-Gámez JA; Carrasco MC; Navascués J; Cuadros MA; López-Giménez JF; Cutillas PR; Martín-Oliva D
    Exp Eye Res; 2019 Nov; 188():107790. PubMed ID: 31494107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells.
    Moolmuang B; Ruchirawat M
    J Pharm Pharmacol; 2021 Mar; 73(1):40-51. PubMed ID: 33791808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways.
    Zhou S; Dai Z; Wang L; Gao X; Yang L; Wang Z; Wang Q; Liu Z
    J Cell Mol Med; 2021 Dec; 25(24):11157-11169. PubMed ID: 34761497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ataxia-Telangiectasia and RAD3-Related and Ataxia-Telangiectasia-Mutated Proteins in Epithelial Ovarian Carcinoma: Their Expression and Clinical Significance.
    Lee B; Lee HJ; Cho HY; Suh DH; Kim K; No JH; Kim H; Kim YB
    Anticancer Res; 2015 Jul; 35(7):3909-16. PubMed ID: 26124337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
    Li L; Chang W; Yang G; Ren C; Park S; Karantanos T; Karanika S; Wang J; Yin J; Shah PK; Takahiro H; Dobashi M; Zhang W; Efstathiou E; Maity SN; Aparicio AM; Li Ning Tapia EM; Troncoso P; Broom B; Xiao L; Lee HS; Lee JS; Corn PG; Navone N; Thompson TC
    Sci Signal; 2014 May; 7(326):ra47. PubMed ID: 24847116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR).
    Wang LW; Jiang S; Yuan YH; Duan J; Mao ND; Hui Z; Bai R; Xie T; Ye XY
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.
    Gout J; Perkhofer L; Morawe M; Arnold F; Ihle M; Biber S; Lange S; Roger E; Kraus JM; Stifter K; Hahn SA; Zamperone A; Engleitner T; Müller M; Walter K; Rodriguez-Aznar E; Sainz B; Hermann PC; Hessmann E; Müller S; Azoitei N; Lechel A; Liebau S; Wagner M; Simeone DM; Kestler HA; Seufferlein T; Wiesmüller L; Rad R; Frappart PO; Kleger A
    Gut; 2021 Apr; 70(4):743-760. PubMed ID: 32873698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.